Skip to content

Influence of Sodium Intake in spondyLoarthriTes

Sodium Intake in spondyLoarthriTes: Analysis of the Influence on the Activity of the Disease and the Therapeutic Response to Anti IL-17A Agents.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06259890
Acronym
SALT
Enrollment
250
Registered
2024-02-14
Start date
2024-01-30
Completion date
2027-05-31
Last updated
2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Psoriatic, Spondyloarthritis, Axial

Keywords

Sodium intake

Brief summary

The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.

Interventions

OTHERmeasurement of salt intake

measurement of salt intake without intervention

Sponsors

French Society of Rheumatology
CollaboratorOTHER
Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis * women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)

Exclusion criteria

* patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists. * current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old. * patients on systemic corticosteroids with corticosteroid therapy \> 10 mg prednisone equivalent * pregnant woman

Design outcomes

Primary

MeasureTime frameDescription
sodium intakeday of inclusion, monday and tuesday followingaverage sodium concentration in urine for the week

Countries

France

Contacts

Primary ContactGuillaume BOITEUX, PhD
gboiteux@chu-besancon.fr+33381218957
Backup ContactElise Robert
e1robert@chu-besancon.fr0381219086

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026